Lipoprotein apheresis – Shortening of treatment intervals reduces cardiovascular events: Case reports

2019 ◽  
Vol 40 ◽  
pp. 125-130
Author(s):  
Theresa Berent ◽  
Robert Berent ◽  
Helmut Sinzinger
2020 ◽  
Vol 9 (6) ◽  
pp. 1925 ◽  
Author(s):  
Zara Latif ◽  
Nadish Garg

With the expanded legalization of marijuana, its medical and recreational use have sharply increased over the past decade. A wide array of new forms of cannabis is available on the market today, and the potencies are ten times those of forms previously tested, meaning that the true impact of marijuana on the cardiovascular system remains unclear. Cannabis mainly exerts its effects via the sympathetic and parasympathetic nervous systems, with different doses affecting different cannabinoids receptors. Studies have shown that marijuana plays a role in thrombosis, inflammation, and atherosclerosis. Case reports have linked marijuana use to myocardial infarction, cardiac arrythmias, cardiomyopathies, stroke, and arteritis. Most patients are young, healthy men with no cardiovascular risk factors; however, the patient population is expected to change to include older individuals in the future. The widespread public perception of safety accompanying marijuana use has contributed to its increased use among the elderly, who are the most at risk population for acute cardiovascular events. In this review, we aim to provide a basic understanding of the physiological effects of marijuana on the cardiovascular system and to review the current literature regarding cardiovascular diseases linked to marijuana use in adults.


2020 ◽  
Vol 7 (3) ◽  
pp. 25
Author(s):  
Ulrich Julius ◽  
Solveig Kuss ◽  
Sergey Tselmin ◽  
Ulrike Schatz ◽  
Stefan R. Bornstein

Lipoprotein apheresis (LA) is an effective tool to reduce cardiovascular events (CVEs) in high-risk patients with elevations of low density lipoprotein-cholesterol (LDL-C) and/or Lipoprotein(a) (Lp(a)). All patients included into this retrospective analysis had experienced CVEs before the start of the LA therapy. We compared personal and lab data in two groups: CVEx/0 (n 60) with no new events during LA therapy, CVEx/1+ (n 48) with at least one new event. Patients of Group CVEx/1+ were about 5 years older when they had started the extracorporeal therapy, and they experienced more CVEs prior to that timepoint. There was a positive correlation between the number of CVEs before and during LA therapy. No differences were seen with respect to lipid concentrations, even after a correction of LDL-C concentrations for the LDL-C transported with Lp(a) particles. LA sessions effectively reduced both LDL-C and Lp(a). Lp(a) levels measured before LA sessions were lower than those measured initially. It appeared difficult to reach the target values for LDL-C published in the ESC/EAS Guideline in 2019, although all patients were maximally treated including drugs when tolerated. In conclusion, it will be important to initiate an LA therapy earlier, at least after a second CVE and at a younger age.


2013 ◽  
Vol 14 (1) ◽  
pp. 45-50 ◽  
Author(s):  
K. Taseva ◽  
S. Fischer ◽  
J. Passauer ◽  
N. Weiss ◽  
S.R. Bornstein ◽  
...  

2018 ◽  
Vol 57 (5) ◽  
pp. 661-664 ◽  
Author(s):  
Federico Bigazzi ◽  
Francesco Sbrana ◽  
Daniele Berretti ◽  
Zenti Maria Grazia ◽  
Sabina Zambon ◽  
...  

2021 ◽  
Author(s):  
Takeo Ishii ◽  
Masatsune Ogura ◽  
Haruka Nakamori ◽  
Mika Hori ◽  
Mariko Harada-Shiba ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document